血管内皮生长因子与肿瘤放射治疗

实体肿瘤生长、浸润和转移必须有肿瘤血管形成，血管形成是在一系列血管生长因子的调控下实现的，血管内皮生长因子（VEGF）是最重要的血管形成因子。肿瘤放疗能影响肿瘤组织及血液中VEGF的表达水平，VEGF表达水平又能预示肿瘤放疗的疗效，因此肿瘤放疗与抗VEGF治疗的结合将是一个具有诱人前景的肿瘤治疗方案。     

抗血管内皮生长因子药物治疗肿瘤的耐药机制

抗血管内皮生长因子(VEGF)药物治疗晚期肿瘤过程中所出现的耐药,可能与其他血管发生通路的激活、骨髓干细胞的动员、管周细胞及围管浸润的演变等相关.因此,探讨发生耐药的机制将有助于更深入了解正常组织、肿瘤及药物间的相互作用关系,并可能提示肿瘤治疗的新靶点.     

血管内皮生长因子靶向抗肿瘤药物的研究与开发

血管内皮生长因子(VEGF)家族在肿瘤血管生成与转移中起关键作用,从不同途径阻断VEGF的生物学作用可以达到治疗肿瘤的目的。目前以VEGF及其受体为靶标研究开发了抗体、可溶性受体、酪氨酸激酶抑制剂、核酸和多肽类药物,均取得了较好的进展。     

血管内皮生长因子靶向抗肿瘤药物的研究与开发

血管内皮生长因子（VEGF）家族在肿瘤血管生成与转移中起关键作用,从不同途径阻断VEGF的生物学作用可以达到治疗肿瘤的目的。目前以VEGF及其受体为靶标研究开发了抗体、可溶性受体、酪氨酸激酶抑制剂、核酸和多肽类药物,均取得了较好的进展。     

血管内皮生长因子在恶性肿瘤患者表达的临床研究

目的 通过测定血管内皮生长因子（VEGF）在肿瘤患者血清及恶性渗出液中的含量，以明确VEGF能否作为肿瘤标志物。方法 通过酶联免疫吸附法测定VEGF在健康人、肿瘤患者血清及恶性渗出液中的含量。结果 恶性肿瘤患者血清中VEGF含量较健康组高，且有显著差异（P〈0．01），但多数肿瘤转移与非转移组比较无差异（肝癌患者除外），非转移性胃肠道肿瘤患者血清中VEGF与CEA、CA19-9有相关性，其他恶性肿瘤血清中VEGF与CEA、CAl9．9均无相关性。22例肺癌患者渗出液中VEGF中位数229．2pg／ml，比其血清中VEGF中位数高（62．2pg/ml）。有恶性渗出液患者血清中VEGF与其渗出液中VEGF无相关性。渗出液中VEGF与其CEA、CA19-9及LDH亦无相关性。肺癌患者经治疗血清中VEGF随病情好转而下降，也可随病情进展而升高。结论 ①恶性肿瘤患者血清中VEGF水平比健康人高。②VEGF可作为一个非特异性的肿瘤标志物，且与治疗疗效呈正相关。     

血管内皮生长因子C及其受体在血液肿瘤中的研究进展

血管/淋巴管新生是生物体重要的生理过程,在恶性肿瘤进展和浸润转移过程中也发挥着重要作用。血管内皮生长因子C（VEGF-C）可通过与其受体VEGFR-2,3信号途径诱导血管/淋巴管新生。许多血液肿瘤中均有VEGF-C及受体表达,它与临床分期、耐药、疗效和预后等有一定关系。随着对其研究的深入,针对VEGF-C及其受体靶点的治疗可能成为血液肿瘤治疗的新手段。     

血管内皮生长因子与肿瘤

血管形成是肿瘤生长和转移的重要条件，而血管内皮生长因子(VEGF)对肿瘤的血管形成具有很突出的作用，就VEGF与肿瘤予以综述。     

血管内皮生长因子与肿瘤

血管内皮生长因子与肿瘤陶厚权王瑞年林言箴作者单位：上海第二医科大学瑞金医院外科（２０００２５）血管通透因子（ｖａｓｃｕｌａｒｐｅｒｍｅａｂｉｌｉｔｙｆａｃｔｏｒ，ＶＰＦ）因具有增加血管通透性而得名，同时它还能促进血管内皮细胞分裂增殖，故又有血管内皮生...     

Vascular endothelial growth factor

Vascular endothelial growth factor (VEGF) is a hypoxia-inducibleangiogenesis and vascular permeability factor which is expressedin high amounts in perinecrotic palisading cells inhuman glioblastomas. In vitro VEGF gene expression isenhanced approximately ten times by hypoxia. Current evidencesuggests, that hypoxia is also the driving forcefor VEGF gene expression in glioblastoma cells invivo and represents the most important trigger fortumor angiogenesis and edema. Our approaches to inhibittumor angiogenesis and edema formation in glioblastoma patientswill concentrate on the disruption of VEGF/VEGF receptorsignal transduction pathway in vivo.     

血管内皮生长因子与肿瘤

血管形成是肿瘤生长和转移的重要条件 ,而血管内皮生长因子 (VEGF)对肿瘤的血管形成具有很突出的作用 ,就VEGF与肿瘤予以综述     

血管内皮生长因子及其受体与骨肉瘤关系的研究进展

血管内皮生长因子（ＶＥＧＦ）是一种序列高度保守、高度特异性的促血管内皮细胞生长因子,广泛分布于人和动物体内的大脑、肾脏、肝脏、脾脏、胰腺和骨骼等组织中,对内皮细胞具有强烈的促有丝分裂作用,刺激血管内皮细胞增殖和血管通透性增加,促进新生血管形成。ＶＥＧＦ通过与血管内皮细胞表面受体（ＶＥＧＦＲ）特异性结合发挥生物学效应。抑制ＶＥＧＦ及ＶＥＧＦＲ的活性可以减缓或阻滞骨肉瘤侵袭和转移。研究表明,ＶＥＧＦ及ＶＥＧＦＲ对肿瘤血管及淋巴管的生成及肿瘤侵袭和转移起重要作用。本文对ＶＥＧＦ及ＶＥＧＦＲ与骨肉瘤血管与淋巴管生成及其侵袭与转移的关系作一综述。     

肿瘤抗血管内皮生长因子与放射及免疫联合治疗研究进展

目前的很多基础研究和临床研究,都在探讨血管内皮生长因子(VEGF)抑制剂与放疗、免疫治疗相结合的作用机制、联合方案、治疗疗效和不良反应等,现有研究证实抗VEGF治疗可以提高放疗对肿瘤的控制,但怎样在疗效最大化、伤害最小化的基础上将这3种治疗手段合理运用,仍有待进一步探索。本文将对抗VEGF治疗与放疗、免疫治疗联合抗肿瘤的相关机制及研究进展作一综述。     

血管内皮生长因子与多发性骨髓瘤

多发性骨髓瘤(MM)是目前仍缺乏根治手段的浆细胞肿瘤,与骨髓微环境异常密切相关.研究表明,血管内皮生长因子(VEGF)是肿瘤微环境中血管形成最重要的生长因子,直接参与MM的发病和进展.目前正在MM患者中开展VEGF相关途径的靶向治疗.     

Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages

Genetic depletion of macrophages in Polyoma Middle T oncoprotein (PyMT)-induced mammary tumors in mice delayed the angiogenic switch and the progression to malignancy. To determine whether vascular endothelial growth factor A (VEGF-A) produced by tumor-associated macrophages regulated the onset of the angiogenic switch, a genetic approach was used to restore expression of VEGF-A into tumors at the benign stages. This stimulated formation of a high-density vessel network and in macrophage-depleted mice, was followed by accelerated tumor progression. The expression of VEGF-A led to a massive infiltration into the tumor of leukocytes that were mostly macrophages. This study suggests that macrophage-produced VEGF regulates malignant progression through stimulating tumor angiogenesis, leukocytic infiltration and tumor cell invasion.     

Vascular endothelial growth factor expression predicts outcome after primary radiotherapy for head and neck squamous cell cancer

AimsTo establish whether the expression of vascular endothelial growth factors (VEGFs) predicts prognosis in patients treated with primary radiotherapy for cancers of the upper aerodigestive tract.Materials and methodsA retrospective analysis was undertaken of VEGF and VEGF-D expression in tumour tissue in pre-treatment biopsies from 27 patients who had been treated with primary radiotherapy for stage II–IV squamous head and neck carcinomas. Serial sections (4 μm) were cut from formalin-fixed, paraffin-embedded specimens and stained with monoclonal antibodies using standard immunoperoxidase methods. Two independent investigators assessed the staining intensity in a randomised, blind manner. Both negative and positive controls (placenta and/or tonsil) were included in the staining procedure. All patients were followed for a minimum of 5 years, or until death. Local control and overall survival were taken as end points for the comparative analysis between patients whose tumours expressed low levels and those that expressed high levels of the two growth factors. Comparisons were made using the Log-rank test with Kaplan–Meier actuarial survival analysis.ResultsIn patients with tumours expressing low levels of VEGF, 5-year local control was seen in 75% compared with 18% for those with high levels; overall survival was 75 and 23%, respectively. For those with low levels of VEGF-D, 5-year local control was 64% compared with 17% for those with high levels; overall survival was 58 and 20%, respectively.ConclusionOur results suggest that the expression of endothelial growth factors in squamous head and neck cancers may predict outcome after radiotherapy.     

血管内皮生长因子与肾细胞癌

血管内皮生长因子(VEGF)在肾细胞癌组织中高表达,主要受VHL基因和组织缺氧调控,可作为判断肾细胞癌患者肿瘤进展和预后的标志物.近年来将抗VEGF靶向药物用于肾细胞癌治疗,取得良好的临床疗效.     

血管内皮生长因子受体-1与肿瘤

血管内皮生长因子受体-1（VEGFR-1）通过其酪氨酸激酶活性调节肿瘤血管的新生从而影响肿瘤的发生、发展和转移。近年研究发现一些肿瘤细胞本身也可以表达VEGFR-1,抗VEGFR-1抗体不仅可以对表达VEGFR-1的肿瘤血管内皮发生直接的抗血管生成活性,也可以通过旁分泌的配体活化VEGFR-1阳性肿瘤细胞而直接影响肿瘤的发生、发展。